IgA Nephropathy, Lymphocyte Homing and IgA Class Switch

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01775527

Acronym

NIDOCIGA

Enrollment

Registered

2013-01-25

Start date

2013-02-28

Completion date

2016-06-30

Last updated

2016-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA Nephropathy

Brief summary

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure. This disease was described as a distinct entity in 1968 by J Berger and N Hinglais. The aetiology and the pathogenesis remain still obscure. Clinical observations and immunisation studies indicate that IgAN represents a dysregulation of the immune system, rather than an intrinsic renal abnormality. Twenty years ago, some authors proposed the mucosa-bone marrow axis to explain the pathogenesis of the disease. Mucosal IgA plasmocytes are displaced and take up residence in systemic sites. The unusual characteristics featured by the IgA produced by these cells (charge, size, glycosylation) drive their accumulation, deposition and mesangial activation characteristic of IgAN. Evidence is emerging that altered lymphocyte homing may ultimately explain this aberrant localization.

Interventions

OTHERblood test

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Age \> 18 and \< 70 years * IgA nephropathy documented by the kidney biopsy in the six months preceding the inclusion * Glomerular filtration rate (MDRD formula as simplified) \< 90 ml/mn and \> 30 ml/mn/1,73 m2 * Consent form signed

Exclusion criteria

* Patients with cirrhosis or chronic liver disease * Patients with a history of Crohn's disease or celiac disease * Patients who received treatment with corticosteroids or affiliates for six months * Patients who received a live attenuated vaccine during the past 4 weeks * Patients with a known infection such as HIV, hepatitis B or C * Patients who presented with a serious infection during the last month * Breastfeeding women * Patients not affiliated with a social security scheme * Under guardianship patient

Design outcomes

Primary

Measure	Time frame
The Primary Outcome Measure of this study is the level of expression of the molecules of intestinal localization.	30 minutes

Secondary

Measure	Time frame
The secondary outcome measure is the level of expression of the homing molecules in lymphocytes B IgA memory	30 minutes

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026